Imatinib treatment induces CD5+ B lymphocytes and IgM natural antibodies with anti-leukemic reactivity in patients with chronic myelogenous leukemia.

Imatinib mesylate is a first line treatment of Chronic Myelogenous Leukemia and of a rare form of gastrointestinal stromal cancer, where the response to the drug is also linked to the immune system activation with production of antineoplastic cytokines. In this study, forty patients in the chronic p...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Silvia Catellani, Ivana Pierri, Marco Gobbi, Alessandro Poggi, Maria Raffaella Zocchi
Format: article
Langue:EN
Publié: Public Library of Science (PLoS) 2011
Sujets:
R
Q
Accès en ligne:https://doaj.org/article/43a888f74f0d45ed92183b04cada8d05
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!